Market Research Logo

Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Alzheimer’s disease and idiopathic pulmonary fibrosis, and stroke among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc Key Recent Developments

Mar 12,2019 Biogen to sell biologics production site to Fujifilm for $890m
Mar 04,2019 Biogen to buy gene therapy firm Nightstar Therapeutics for $800m
Mar 01,2019 Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
Feb 28,2019 Biogen Further Expands Presence in China with Approval of SPINRAZA (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Biogen Inc - Key Facts
Biogen Inc - Key Employees
Biogen Inc - Key Employee Biographies
Biogen Inc - Major Products and Services
Biogen Inc - History
Biogen Inc - Company Statement
Biogen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 - Company Analysis
Company Overview
Biogen Inc - Business Description
Product Category: Biosimilars
Overview
Performance
Product Category: Multiple Sclerosis
Overview
Performance
Product Category: Others
Overview
Performance
Product Category: Spinal Muscular Atrophy
Overview
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Other
Performance
Geographical Segment: US
Performance
R&D Overview
Biogen Inc - Corporate Strategy
Biogen Inc - SWOT Analysis
SWOT Analysis - Overview
Biogen Inc - Strengths
Biogen Inc - Weaknesses
Biogen Inc - Opportunities
Biogen Inc - Threats
Biogen Inc - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Biogen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
Mar 12, 2019: Biogen to sell biologics production site to Fujifilm for $890m
Mar 04, 2019: Biogen to buy gene therapy firm Nightstar Therapeutics for $800m
Mar 01, 2019: Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
Feb 28, 2019: Biogen Further Expands Presence in China with Approval of SPINRAZA (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Jan 29, 2019: Biogen reports record revenues for both the full year and Q4 2018, $13.5 billion and $3.5 billion, respectively
Jan 07, 2019: Biogen signs two deals to address neurological disorders
Dec 06, 2018: Top Canadian researchers at the helm of pioneering Canadian Proactive Cohort Study for People Living with MS (CanProCo)
Nov 29, 2018: International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Nov 29, 2018: International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Nov 19, 2018: Biogen and Amicus win UK Prix Galien awards for rare disease medicines
Section 6 - Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Biogen Inc, Key Facts
Biogen Inc, Key Employees
Biogen Inc, Key Employee Biographies
Biogen Inc, Major Products and Services
Biogen Inc, History
Biogen Inc, Other Locations
Biogen Inc, Subsidiaries
Biogen Inc, Joint Venture
Biogen Inc, Key Competitors
Biogen Inc, Ratios based on current share price
Biogen Inc, Annual Ratios
Biogen Inc, Annual Ratios (Cont...1)
Biogen Inc, Annual Ratios (Cont...2)
Biogen Inc, Interim Ratios
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Biogen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Biogen Inc, Performance Chart (2014 - 2018)
Biogen Inc, Ratio Charts
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report